Bellicum Pharmaceuticals Inc  

(Public, NASDAQ:BLCM)   Watch this stock  
Find more results for Kevin D Huber´┐Ż
+0.08 (0.32%)
Real-time:   1:41PM EDT
NASDAQ real-time data - Disclaimer
Currency in USD
Range 23.58 - 24.25
52 week 18.20 - 33.63
Open 23.79
Vol / Avg. 51,989.00/296,867.00
Mkt cap 634.31M
P/E     -
Div/yield     -
EPS -32.82
Shares 26.38M
Beta     -
Inst. own 51%
Jun 17, 2015
Bellicum Pharmaceuticals Inc Annual Shareholders Meeting - 11:00AM EDT - Add to calendar
Jun 2, 2015
Bellicum Pharmaceuticals Inc at Jefferies Global Healthcare Conference - 2:30PM EDT - Add to calendar
May 11, 2015
Q1 2015 Bellicum Pharmaceuticals Inc Earnings Release
Mar 11, 2015
Q4 2014 Bellicum Pharmaceuticals Inc Earnings Call
Mar 11, 2015
Q4 2014 Bellicum Pharmaceuticals Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '15) 2014
Net profit margin -7250.47% -4715.75%
Operating margin -7297.20% -3248.36%
EBITD margin - -782.12%
Return on average assets -16.20% -79.69%
Return on average equity -16.51% -104.47%
Employees 35 -
CDP Score - -


2130 W Holcombe Blvd Ste 800
HOUSTON, TX 77030-3307
United States - Map
+1-832-3841100 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Bellicum Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing cellular immunotherapies for various forms of cancer, including hematological cancers and solid tumors, as well as orphan inherited blood disorders. Its product pipeline includes clinical product candidates: BPX-501, which is an adjunct T-cell therapy administered after allogeneic hematopoietic stem cell transplantation; BPX-201, which is a dendritic cell cancer vaccine; and Preclinical product candidates: BPX-701, which is a T cell receptor (TCR) product candidate for solid tumors; BPX-401, which is a CAR-T product candidate for hematological cancers that express the CD19 antigen, and BPX-601, which is a TCR product candidate for solid tumors expressing the preferentially-expressed antigen in melanoma (PRAME). Its Chemical Induction of Dimerization (CID) technology platform, engineers and controls components of the immune system in real time.

Officers and directors

James Brown Chairman of the Board
Age: 50
Bio & Compensation  - Reuters
Thomas J. Farrell President, Chief Executive Officer, Director
Age: 51
Bio & Compensation  - Reuters
Alan A. Musso CPA Chief Financial Officer, Treasurer
Age: 53
Bio & Compensation  - Reuters
Annemarie Moseley M.D., Ph.D. Chief Operating Officer, Senior Vice President - Clinical Development and Regulatory Affairs
Age: 59
Bio & Compensation  - Reuters
Ken Moseley J.D. Senior Vice President, General Counsel
Age: 58
Bio & Compensation  - Reuters
Peter L. Hoang Senior Vice President - Business Development and Strategy
Age: 43
Bio & Compensation  - Reuters
Kevin M. Slawin M.D. Chief Medical Officer, Chief Technology Officer, Director
Age: 54
Bio & Compensation  - Reuters
David M. Spencer Ph.D. Chief Scientific Officer
Age: 52
Bio & Compensation  - Reuters
Joseph Senesac Vice President - Manufacturing
Age: 44
Bio & Compensation  - Reuters
Reid M. Huber Ph.D. Director
Age: 42
Bio & Compensation  - Reuters